- Home
- RVPH vs VRCA Comparison
RVPH vs VRCA Comparison
Compare RVPH & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- VRCA
- Stock Information
- Founded
- RVPH 2006
- VRCA 2013
- Country
- RVPH United States
- VRCA United States
- Employees
- RVPH N/A
- VRCA N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- RVPH Health Care
- VRCA Health Care
- Exchange
- RVPH Nasdaq
- VRCA Nasdaq
- Market Cap
- RVPH 36.7M
- VRCA 43.0M
- IPO Year
- RVPH N/A
- VRCA 2018
- Fundamental
- Price
- RVPH $0.90
- VRCA $0.53
- Analyst Decision
- RVPH Strong Buy
- VRCA Hold
- Analyst Count
- RVPH 5
- VRCA 5
- Target Price
- RVPH $9.00
- VRCA $6.00
- AVG Volume (30 Days)
- RVPH 515.2K
- VRCA 263.8K
- Earning Date
- RVPH 05-15-2025
- VRCA 05-13-2025
- Dividend Yield
- RVPH N/A
- VRCA N/A
- EPS Growth
- RVPH N/A
- VRCA N/A
- EPS
- RVPH N/A
- VRCA N/A
- Revenue
- RVPH N/A
- VRCA $7,179,000.00
- Revenue This Year
- RVPH N/A
- VRCA $127.85
- Revenue Next Year
- RVPH N/A
- VRCA $105.09
- P/E Ratio
- RVPH N/A
- VRCA N/A
- Revenue Growth
- RVPH N/A
- VRCA N/A
- 52 Week Low
- RVPH $0.49
- VRCA $0.38
- 52 Week High
- RVPH $4.28
- VRCA $9.36
- Technical
- Relative Strength Index (RSI)
- RVPH 48.40
- VRCA 43.40
- Support Level
- RVPH $0.85
- VRCA $0.49
- Resistance Level
- RVPH $1.15
- VRCA $0.73
- Average True Range (ATR)
- RVPH 0.11
- VRCA 0.07
- MACD
- RVPH 0.00
- VRCA -0.01
- Stochastic Oscillator
- RVPH 33.28
- VRCA 10.77
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.